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Solvent driven phase transitions of acyclovir – the role of water 
and solvent polarity  
Karol P. Nartowskia,b, *, Julia Karabina, Alexander L. Morrittb, Maciej Nowaka, László Fábiánb, 
Bożena Karolewicza, Yaroslav Z. Khimyakb, * 
Acyclovir, an antiviral purine derivative listed on the WHO Model List of Essential Medicines, is commonly used in several 
different dosage forms from tablets to gels, oleogels and suspensions. Although temperature driven phase transitions of its 
commercially available 3:2 hydrate have been known since 2011, information on the solvent driven phase transitions of this 
drug has been limited. This study identifies the pathways of transformations of acyclovir forms I and V induced by organic 
solvents and water using the method of solution mediated phase transformation. The 3:2 hydrate, form V, undergoes 
dehydration to anhydrous form I in methanol, ethanol and N,N-dimethylformamide. Form I converts to anhydrous form II in 
dry methanol and N,N-dimethylformamide, while increased water content in the solvent prevents the transformation of 
form I to form II. Both forms I and V yield a gel-like material in dimethyl sulfoxide, composed of highly crystalline form II and 
reported here for the first time. Furthermore, significant differences in the thermal dehydration process of forms V and VI 
were observed using VT FTIR, including the first time report on a novel metastable ACV form VII formed upon dehydration 
of ACV dihydrate (form VI). High resolution solid-state NMR spectra of two anhydrous polymorphs (forms I and II) and two 
hydrates (forms V and VI) supported by DFT calculations using the CASTEP code are also presented.  
.
Introduction 
Acyclovir, (ACV, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy) 
methyl]-6H-purin-6-on) a guanine derivative, is an important 
antiviral drug listed on the WHO Model List of Essential 
Medicines (Figure 1A). ACV belongs to BCS class III 
(Biopharmaceutical Classification System) indicating the drug to 
be soluble in water but to have limited permeability.1 This is in 
line with its limited bioavailability (5 to 30%), which varies 
between individuals.2 Furthermore, it is known that different 
ACV solid forms display substantial differences in dissolution 
kinetics, which may affect the bioavailability of the drug.2,3  
ACV can form varied hydrogen bonding networks due to the 
presence of eight potential hydrogen donors/acceptors and a 
flexible side chain, which results in four polymorphs and two 
hydrate forms reported to date. The reported crystalline phases 
were obtained using polymer-induced heteronucleation (PIHn) 
and at increased temperatures by Lutker et al.4 and through the 
application of dynamic vapour sorption by Terada et al. (Figure 
1B, ESI Figure S11).5  
Based on the studies of Lutker et al.4 and Terada et al.5 ACV 
forms two hydrates – the commercially available 3:2 ACV:water 
hydrate (form V) and a 1:2 dihydrate (form VI), two anhydrous 
forms, I and II, and two forms stable only at high temperature, 
forms III and IV.4 ACV form V was first reported by Birnbaum et 
al. in 1980s.6,7 The anhydrous ACV form I (nomenclature 
proposed by Lutker et al.4) can be obtained by heating the 
commercial form (form V) to 180 °C followed by cooling to room 
temperature or via crystallization of acyclovir from methanol in 
the presence of the polymer Nylon 6. The second anhydrous 
form, ACV form II, can be obtained via solution crystallisation of 
the commercial form of acyclovir in methanol at 68 °C in a 
closed vial followed by evaporating the solvent under 
continuous heating4 or by precipitation from NNDMF using 
acetonitrile as antisolvent.5 Dynamic vapor sorption studies 
carried out by Terada et al. have shown that above 90% RH form 
I transforms into dihydrate (form VI), while form II transforms 
to 3:2 hydrate (form V) above 95% RH.5 The metastable 
anhydrous form III can be obtained by heating the commercial 
form V between 130 and 150 °C and rapidly returns to the form 
V during cooling upon exposure to atmospheric water. Further 
heating of the metastable form III to 180 °C leads to the 
formation of the high-temperature stable form IV, which after 
cooling to room temperature undergoes a phase change to 
form I, which is stable at room temperature.4 The dihydrate 
form VI was first obtained during polymorph screening using 
polymer induced heteronucleation with poly(ethylene 
terephthalate) and polypropylene (Figure 1B).4  
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Figure 1. A. Structure of acyclovir with carbon and nitrogen labeling. B. ACV phase transitions described by Terada et al. and Lutker et al. Blue arrows indicate humidity driven phase 
transitions, red arrows, temperature driven phase transitions while gray arrows are due to solvent or PIH crystallisation. 
Through the analysis of purine ring arrangements in ACV crystal 
structures, followed by the study of dynamic water sorption, 
Terada et al. proposed explanations for the possible directions 
of ACV phase transformations. It was shown that form V did not 
convert to anhydrous form II and anhydrous form I did not 
undergo direct conversion to form V at 25 °C and RH range of 0-
95%. On the other hand, form I could convert to form V only in 
an indirect way by forming a dihydrate (form VI) at 95% RH and 
subsequent transformation to form V at 20% RH. This 
observation was attributed to similar arrangements of the 
purine rings in the crystal structures of forms I and VI, and the 
substantial difference in the ring arrangement between the 
forms I and V. Furthermore, Terada et al. hypothesized that 
anhydrous forms I and II do not undergo direct reciprocal 
transformation due to different arrangements of the purine 
rings in both crystal structures.5 In this manuscript we show that 
ACV form I undergoes transformation to ACV form II in 
anhydrous methanol, ethanol, N,N-dimethylformamide and 
dimethylsulfoxide. To the best of our knowledge, very little is 
known about solvent induced phase transitions of ACV. This 
drug is a representative of purine derivatives, a wide group of 
biologically active substances frequently used in drug discovery 
and an important group of pharmaceuticals and biologically 
active molecules essential for all living organisms. Therefore 
ACV may serve as a model compound to identify solvent effects 
on the transformations of N-substituted purine derivatives and 
to help in crystal engineering efforts to expand the solid-state 
landscape of these compounds. 
Polymorph screening is typically carried out by modification of 
crystallisation conditions e.g. temperature, pressure or by using 
different solvents, which enables the formation of distinct 
assembly patterns between reacting molecules.8 Furthermore, 
as presented by Zhang et al.9 and Gu et al.10 solution mediated 
phase transformation (SMPT) is an effective method for 
polymorph screening, including screening for new solvates or 
cocrystals. This process involves crystallisation or slurrying of 
the starting material in solvents with different polarities or by 
the manipulation of the water activity by using a mixture of 
organic solvents and water.11–15 
Despite the broad use of acyclovir in a variety of dosage forms, 
including tablets, gels, creams, oleo gels or suspensions for both 
systemic and topical treatments, there is limited knowledge 
available on polymorphic changes driven by solvent. In this 
work we address this gap by systematic investigation of solvent 
induced phase transitions of commercially available ACV form V 
(3:2 ACV:H2O hydrate) and anhydrous ACV form I using 15 
different solvents. We also report on the effect of hydrate water 
of ACV hydrate forms V and VI (dihydrate) on the temperature 
driven dehydration and phase transitions of ACV. Using a 
combination of state-of-the-art thermal (DSC, TGA), 
spectroscopic (solid-state NMR, FTIR) and diffraction 
characterization methods supported by computational NMR 
crystallography (DFT calculations using CASTEP code) we 
revisited structural information on some existing forms of ACV, 
which enabled us to gain a more detailed insight into the 
thermal desolvation of ACV hydrates and solvent induced 
transformations of ACV forms I and V. We also report the 
formation of a new high-temperature phase as the result of the 
desolvation of form VI. This work describes polymorphic 
screening and transformations of ACV using a broad range of 
organic solvents commonly used in the synthesis and drug 
product development of biologically active substances.  
Experimental 
Materials:  
ACV form V was kindly donated by Pharmaceutical 
Manufacturing Company Hasco-Lek S. A. (Wroclaw, Poland). 
Solvents of analytical grade used in the study were purchased 
from Sigma-Aldrich (acetone, 1-propanol, 2-propanol, 
1- butanol, ethyl acetate, N,N-dimethyloformamide, dimethyl 
sulfoxide), J. T. Baker (acetonitrile, methanol, ethanol, 
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dichloromethane, trichloromethane, toluene) and Chemsolve 
(acetic acid) and used directly without further purification. 
Methods: 
Recrystalisation of ACV form V. In order to confirm the 
polymorphic homogeneity of commercial ACV form V used in 
the study the received material was compared with freshly 
prepared ACV form V. 100 mg of ACV form V was dissolved in 
40 ml of distilled water at 37 °C and left to recrystallise. The 
crystals were collected after 24 hours and analysed using PXRD 
(Powder X-ray Diffraction) and DSC (Differential Scanning 
Calorimetry). 
Preparation of ACV form I. The anhydrous form I of ACV was 
prepared using the method previously described by Lutker et al. 
4 Briefly, 4.5 g of ACV form V (3:2 hydrate) were spread on a 
Petri dish and heated in the oven using a heating rate of 5 
°C/minute from 25 to 180 °C. The material was left at 180 °C for 
30 minutes and then allowed to cool to room temperature. The 
thermal stability of the drug was confirmed using 
thermogravimetric analysis. The maximum mass loss observed 
was 0.4 % after 30 minutes storage of ACV form V at 180 °C (see 
ESI Figure S1 for details). The obtained ACV form I was analysed 
directly after preparation. 
Preparation of ACV form II. The anhydrous form II of ACV was 
obtained using the following methods: (1) slurry of the ACV 
form V crystals (3:2 hydrate) in DMSO for at least one week or 
(2) slurry of anhydrous ACV form I crystals in methanol (MeOH), 
N,N-dimethylformamide (NNDMF) and dimethyl sulfoxide 
(DMSO) for 4 weeks in a desiccator over silica gel.  
Preparation of ACV form VI (1:2 ACV:H2O dihydrate). 150 mg of 
ACV form I was placed into a 10 ml glass vial and gently mixed 
with 1 ml of distilled water to allow the solvent to cover the 
surface of the powder. The vial was left at RT (ca. 22 °C) for 72 
hours. The resulting material was dried on a filter paper prior to 
analysis. 
Selection of the organic solvents for slurry preparation. In this 
study 14 solvents (Table S1) were selected from 7 chemical 
groups proposed by Gu et al., taking into consideration a variety 
of solvent properties, including dielectric constant, dipole 
momentum and propensity of being hydrogen donor or 
acceptor. 10  
Preparation of slurries of ACV form I and form V in organic 
solvents. The commercial ACV form V (3:2 ACV:H2O hydrate) 
and form I, obtained via the dehydration of form V,4 were used 
in slurry crystallisation to evaluate the solvent effect on the 
phase transition of both forms of ACV. For each solvent 300 mg 
of form V or form I were weighed to a 10 ml glass vial and 
subsequently, 1.5 mL of a solvent were pipetted into the vial, 
which was tightly sealed with a cap and protected with Parafilm 
tape to avoid solvent evaporation and atmospheric water 
access. Closed vials were then gently mixed to ensure the 
powder was thoroughly covered by the solvent. The samples 
were left at RT (ca. 22 °C) for four weeks and then analysed 
using PXRD, DSC, TGA and FTIR. The materials in which a solid 
form transformation was observed after 4 weeks of slurrying 
were prepared again and additionally analysed after 7, 14 and 
42 days to evaluate the onset of the transformations in different 
solvents. 
Characterisation techniques: 
Fourier-transform infrared spectroscopy. Room temperature FTIR 
spectra of the materials were obtained using a Nicolet iS50 FT-
IR spectrometer (Thermo Fisher Scientific) using attenuated 
total reflectance (ATR) mode. The samples were analysed in the 
wavelength range from 400 to 4000 cm-1 at 4 cm-1 resolution. 
32 scans were acquired for each material. Variable temperature 
FTIR analysis was performed using a Bruker Vertex 70 
spectrometer with a Specac High Temperature Golden Gate 
Controller between 30.0 to 250.0 °C. 
Powder X-ray diffraction. Powder X-ray diffraction patterns were 
recorded using a Bruker D2 Phaser diffractometer (Bruker AXS, 
Karlsruhe, Germany) with a LynxEye detector and Cu Kα 
radiation (1.5418 Å) and a low background holder. The samples 
were surface dried on a filter paper and gently ground using a 
mortar and pestle. The materials were analysed in the range of 
2Ɵ from 5° to 36° with 0.02° increment and 1 s/step irradiation 
time. The optics of the D2 Phaser diffractometer was a 2.5° 
Soller slit module system, a 0.2 mm divergence slit, a 1 mm air-
scatter screen and a Ni filter. The X-ray tube operated at 30 kV 
and 10 mA. 
Differential scanning calorimetry. DSC measurements were 
performed using a Netzsch DSC 214 Polyma calorimeter. The 
samples were heated in a temperature range from 0 °C to 270 
°C with a heating rates of 2; 5; 10 or 20 °C min-1 using a 50 mL 
min−1 purge of dry nitrogen. Depends on the experimental 
design standard aluminium open, sealed or pin-holed pans 
sealed using a TA crimper were used in all experiments. The 
mass of the analysed samples was 5.0 ± 0.5 mg. An empty pin-
holed DSC pan was used as a reference. 
Thermogravimetric Analysis. TGA thermograms were recorded 
using a Netzsch TG 209 F1 Libra Thermobalance. The mass of 
the analysed materials was 10.0 ± 0.5 mg. The materials were 
placed in aluminium oxide crucibles (Al2O3) and heated from 
25.0 to 270.0 °C with a heating rate of 5 °C/min. The obtained 
thermograms were analysed using the Netzsch Proteus Analysis 
software. 
Critical Water Activity determination in MeOH and NNDMF. ACV 
form I or form V (300 mg) was mixed with methanol/water and 
NNDMF/water mixtures at different mole fraction of water 
corresponding to defined water activity (aw) in the range from 
0.007 to 0.26 in MeOH and 0.03 to 0.38 in NNDMF (See section 
S4 in the ESI for details).11,16,17 The obtained samples were 
withdrawn after 7 days of storage at 25.0 °C and the resultant 
phase was assessed using PXRD. Water content in the residual 
solutions (without ACV crystals) was determined using 
coulometric Karl Fischer Titration (Mettler Toledo) according to 
the protocol described in European Pharmacopoeia.  
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Solid-state NMR. 1H-13C cross-polarization magic angle spinning 
(CP/MAS) solid-state NMR spectra were acquired using a Bruker 
Avance III solid-state NMR spectrometer equipped with a triple 
resonance probe operating at 400.23 MHz for 1H and 100.64 
MHz for 13C. Dry powder samples were packed in 4 mm zirconia 
rotors and rotated at an MAS rate of 10 kHz. The spectra were 
acquired at 25 °C. The Hartmann−Hahn conditions for 1H−13C 
CP/MAS experiments were set with hexamethylbenzene (HMB). 
1H−13C CP/MAS NMR spectra were acquired using 1H π/2 pulse 
length of 3.5 μs and 1H−13C contact time of 2000 µs. For each 
material 384 scans were acquired. Pulse delay was optimised to 
10 s. The 13C chemical shifts were referenced to TMS. 
Computational details. All computations were performed using 
the CASTEP code.18 Chemical shifts were generated for the 
following crystal structures: ACV I (CSD code: MECWIC015) , ACV 
II (CSD code: MECWIC035) , ACV V (CSD code: CEHTAK107) and 
ACV VI (CSD code: WOZPAE5). The geometry optimisation was 
performed with the Perdew−Burke−Ernzerhof (PBE) generalized 
gradient approximation (GGA) exchange correlation density 
functional19 and ultrasoft pseudopotentials20 with the 
Monkhorst-Pack grid sampled with maximum separation of k-
points lower than 0.05 Å-1 and cut-off energy of 800 eV, both 
optimised for convergence. Geometry optimisation was 
performed with both cell dimensions and all heavy atom (C, N, 
O) positions constrained. Chemical shift calculations were 
performed using the gauge including projector augmented 
wave approach (GIPAW)21,22 as implemented in the CASTEP 
code. 
The generated isotropic shielding constants (σcalc) were 
converted to chemical shifts (δcalc) according to the following 
equation: δcalc = σref − σcalc. The reference shielding constant 
value (σref) was taken from the zero intercept of the fit of 
calculated shielding vs experimental chemical shift plot σcalc= 
−x·δexp + σref. 
Results and discussion 
Revisiting ACV solid forms 
Acyclovir is a N-substituted purine derivative, which has six 
distinct crystalline structures described to date.4,5 The rich 
polymorphism of acyclovir suggests that other biologically 
active purine derivatives may have a similar, broad solid-state 
landscape, which is yet to be discovered. Therefore, the 
detailed characterization of packing motifs and phase 
transitions of acyclovir driven by temperature or a solvent may 
serve as a basis for further crystal engineering of this important 
group of pharmaceutically active compounds. 
Four structures of ACV are present in the Cambridge Structural 
Database (CSD, 2017 version)23 including two anhydrous forms 
– ACV form I (CSD ref. code: MECWIC015), ACV form II (CSD ref. 
code: MECWIC035) and two hydrates – ACV form V i.e. 3:2 
hydrate (CSD ref. code: CEHTAK107) and ACV form VI i.e. 
dihydrate (CSD ref. code: WOZPAE5) (Figure 2, Table 1, ESI 
Figure S11).  
 
Figure 2. Experimental and calculated PXRD patters of synthesised ACV forms I (CSD ref. 
code: MECWIC015), II (MECWIC035), V (CEHTAK107), VI (WOZPAE5). 
The structural characterisation of the ACV solid forms stable at 
room temperature, including both ACV hydrates (forms V and 
VI), anhydrous form I and form II via the combination of PXRD 
and solid-state NMR studies supported by computational 
methods enabled us to further understand the structural 
rearrangements and polymorphic transformations of ACV. To 
date only one report has been published on solid-state NMR 
studies of ACV,4 in which the presented 1H-13C CP/MAS spectra 
exhibited several artefacts and significant line broadening. 
This made the full assignment of different carbon sites and 
detailed interpretation of the structural information accessible 
from solid-state NMR very difficult. Herein we present high 
resolution spectra of ACV polymorphs and hydrates, including 
the first report on 1H-13C CP/MAS NMR spectrum of ACV form 
VI.  
 
Table 1. Structural data of ACV forms I, II, V and VI. 
 
 Form I Form II Form V Form VI 
CSD code MECWIC01 MECWIC03 CEHTAK10 WOZPAE 




a/Å 10.9402 4.5518 25.459 6.8386 
b/Å 11.1854 15.0481 11.282 11.3679 
c/Å 8.1167 28.3857 10.768 14.942 
α/° 90.0 90.0 90 82.85 
β/° 108.63 90.0 95.16 82.42 
γ/° 90.0 90.0 90 89.33 
Volume, Å3 941.206 1944.31 3080.34 1142.47 
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Figure 3. 1H-13C CP/MAS NMR spectra of ACV forms I, II, V and VI. B. Comparison of experimental and CASTEP calculated 13C chemical shifts for ACV forms I (CSD ref. code MECWIC015), 
II (CSD ref. code MECWIC035), V (CSD ref. code CEHTAK107) and VI (CSD ref. code WOZPAE5). The dashed line represents an excellent fit. 
The assignment of the 1H-13C CP/MAS solid-state NMR spectra 
is based on the previously reported spectra4,24 and CASTEP 
calculated isotropic chemical shifts (Table S2, Figure 3) for ACV 
forms I (CSD ref. code: MECWIC015), II (CSD ref. code: 
MECWIC035), V (CSD ref. code: CEHTAK107) and VI (CSD ref. 
code: WOZPAE5).The commercial form of ACV (form V) is a 3:2 
ACV/water hydrate, which crystallises in the P21/n space group 
and has three molecules of ACV and two molecules of water in 
the asymmetric unit.4,5,7 The water molecules are located in 
channels along the crystallographic c axis, from where they can 
be removed by heating the material to 180 °C as first indicated 
by Lutker et al.4 The simulated PXRD patterns of ACV form V 
(CSD ref. code: CEHTAK107) are in agreement with experimental 
PXRD traces of the commercially available material (Figure 2), 
with characteristic reflections d(200) = 12.63 Å; d(210) = 8.44 Å; 
d(321) = 4.22 Å and d(30-3) = 3.40 Å. As ACV form V has three 
ACV molecules in the asymmetric unit, 24 peaks were expected 
in the 1H-13C CP/MAS solid-state NMR spectrum. The presence 
of a lower number of peaks (15 peaks) in the spectrum of ACV 
form V is most likely due to very similar local environments of 
ACV carbon atoms in the ACV form V structure, resulting in 
similar values of 13C chemical shifts. The 13C peaks of ACV forms 
are grouped in three distinct regions of the spectrum, i.e. peaks 
of the side chain in the spectral range from 55 to 75 ppm, 
carbon C3 of the purine ring at ca. 115 ppm and peaks of 
carbons C1-C5 of the purine ring in the spectral range from 135 
to 160 ppm. The detailed description of the spectrum is 
presented in ESI Section S7. Despite significant overlapping of 
the 13C peaks of ACV form V (e.g. carbons C8, C6, C5, C2) the 
differences in the peak intensities observed in the spectrum of 
ACV form V support the crystallographic information indicating 
the presence of three ACV molecules in the unit cell.  
Anhydrous ACV form I crystalizes in the P21/c space group with 
four molecules in the unit cell (Z’ = 1). The PXRD patterns of ACV 
form I obtained via dehydration of ACV form V at 180 °C display 
characteristic peaks d(100) = 10.41 Å; d(210) = 4.71 Å; d(20-2) = 
3.71 Å and d(30-2) = 3.12 Å, which are in agreement with 
calculated PXRD patterns and previously published data (Figure 
2).4,5 The 1H-13C CP/MAS NMR spectrum of ACV form I obtained 
via dehydration of ACV form V displays significant differences 
when compared to the starting material (ACV form V). Firstly, 
there are eight peaks in the spectrum of ACV form I (Z’ = 1), 
which can be assigned to the eight carbon atoms of ACV in 
agreement with the crystallographic data. Secondly, the peaks 
of the aliphatic side chain carbons C6 and C8 display a ca. 5 and 
6 ppm up-field shift as compared to ACV form V. This may be 
explained by the involvement of the side chain of ACV form V in 
hydrogen bonding. This leads to short contacts between C6 and 
C8 with electronegative nuclei of neighbouring ACV and water 
molecules.25 
As the water oxygens are more electronegative than carbons 
(and protons) they tend to polarize the electron clouds of 
neighbouring nuclei towards themselves, which results in the 
deshielding effects observed. This phenomenon was described 
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in detail by Spiess et al. for ciprofloxacin hydrates using 
combined application of state of the art solid-state NMR 
methods and CASTEP caluclations.25 The 13C peaks of the purine 
ring of ACV form I undergo only minor changes as compared to 
the structure of ACV form V. This is consistent with a stacked 
arrangement of the rings present in both structures and their 
stabilization via similar hydrogen bonding patterns. 
The second anhydrous form of ACV (form II) was firstly obtained 
by crystallisation of ACV from hot methanol with low yield due 
to the low solubility of ACV in MeOH (0.2 mg/ml).4 We were able 
to obtain the same form during solvent-mediated polymorph 
screening of ACV form I with DMSO, NNDMF and MeOH or ACV 
form V with DMSO. This phase crystallizes in the P212121 space 
group with two molecules in the asymmetric unit (Z = 8). The 
PXRD pattern of ACV form II displays characteristic peaks with 
d(002) = 14.33 Å; d(021) = 7.26 Å and d(101) = 4.57 Å in 
agreement with the calculated PXRD pattern of the MECWIC035 
reference structure (Figure 1). Depending on the solvent used 
for slurry conversion, materials of different crystallinity were 
obtained, as evidenced by the differences in the broadening of 
PXRD peaks. The use of MeOH or NNDMF resulted in lower 
crystallinity, while high crystallinity ACV form II was obtained in 
DMSO (Figures 8 and 9). The presence of two 13C peaks for each 
carbon atom in the spectrum of ACV form II is consistent with 
there being two molecules in the asymmetric unit. The very 
different arrangement of ACV molecules in the crystal 
structures of form I and form II results in different pathways for 
the phase transitions of these two polymorphs on heating. Form 
I transforms to the high temperature form IV above 180 °C, 
while form II does not undergo any phase change before 
melting (see ESI sections S1 and S2 for details). 
Form VI is a dihydrate, with space group symmetry P-1 and two 
ACV and four water molecules in the asymmetric unit. Its 
experimental PXRD pattern, with characteristic peaks d(001) = 
15.04 Å; d(011) = 9.7 Å; d(012) = 6.63 Å and d(210) = 3.30 Å, is 
in agreement with the calculated PXRD pattern for the 
WOZPAE5 structure available in the CSD23 (Table 1, Figure 1). 
Similarly to ACV form II, the number of peaks in the 1H-13C 
CP/MAS spectrum of the dihydrate (form VI) is twice the 
number of carbon atoms in ACV. The unit cell is composed of 
four ACV molecules, with stacking of the purine rings in 
alternating orientations, and eight water molecules organised 
in two channels in close proximity to the aliphatic side chain 
(see ESI Figure S11). The antiparallel arrangement of stacked 
purine rings in ACV form VI and form I was used by Terada et al 
as possible explanation of water sorption induced conversion of 
form I to the hydrate form VI.5 The two ACV molecules forming 
the asymmetric unit of form VI form different hydrogen bonds 
through their carbonyl oxygen atoms. The carbonyl group of C2 
is involved in three hydrogen bonds with two water molecules 
and an amino group, while the carbonyl group of C2’ forms 
hydrogen bond with one water molecule and an amino group. 
This is reflected by a slight upfield shift of C2 to 159.7 ppm from 
158.5 ppm for C2’.  
Temperature induced phase transitions of ACV hydrates 
The temperature driven phase transitions of acyclovir were first 
investigated by Lutker et al.4 followed by further structural 
insights by Terada et al.5 Dehydration and desolvation 
processes often lead to the formation of crystalline phases that 
are not readily accessible otherwise. For example, it was 
demonstrated by our group that the careful removal of 
methanol from its indomethacin solvate results in the formation 
of metastable indomethacin form V.26 Furthermore, the process 
of removal of the solvent may generate disorder in the crystal 
lattice, as was demonstrated for the dehydration of orotic acid 
monohydrate.15 Here we present the results of the desolvation 
process of the two ACV hydrate forms, V and VI, based on the 
combined application of thermal methods (Table 2) and VT FTIR.  
 
 
Figure 4. DSC thermograms (A) and TGA curves (B) of ACV forms I, II, V and VI. 
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Table 2. DSC thermal parameters of ACV forms I, II, V and VI. 
 
The DSC curve of form V (3:2 hydrate) shows a broad 
endothermic peak in the temperature range from 58 to 155 °C 
(Figure 4A) which corresponds to ca. 5.1 % (w/w) loss of water, 
as confirmed using TGA analysis (Figure 4B). Thermally induced 
dehydration of ACV form V results in a gradual transition to the 
metastable form III in the temperature range from 100 to 170 
°C, followed by an endothermic transition with an onset at 
170.3 °C to the high temperature ACV form IV, as previously 
described by Lutker et al.4 and confirmed by our group using VT 
FTIR studies (Figures 5 and 6). Further heating results in melting 
and decomposition of ACV at 257.1 °C.4 Cooling of ACV form IV 
from 180 °C to room temperature results in an exothermic 
transition to form I, which is stable at room temperature (see 
ESI Figure S14).  
Similarly, to form V, the DSC thermogram (Figure 4A) of 
anhydrous form I shows an endothermic transition at 171.2 °C 
corresponding to the formation of form IV as reported by Lutker 
et al. and Terada et al. and further confirmed by our group using 
VT FTIR (see ESI Figure S15).4,5 The melting onset and enthalpy 
of fusion (and decomposition) values of ACV form IV obtained 
either via heating form V or form I are similar, 254.5 °C (99.70 
kJ/mol) and 255.1 °C (97.76 kJ/mol), respectively. In contrast to 
form I, form II does not undergo any polymorphic transitions on 
heating, as reflected in the DSC thermogram (Figure 4A). This 
phase melts within a range of temperatures from 254.1 to 256.7 
°C. The DSC thermogram of form VI (dihydrate) shows a 
complex behavior during heating from room temperature. First 
an endothermic event is observed in the temperature range 
between 45 and 70 °C, which is associated with a water loss of 
ca. 10 wt%, while a second broad endotherm in the 
temperature range from 90 to 160 °C is associated with further 
weight loss of ca. 4 wt% (Figure 4B). The presence of two step 
water loss is consistent across heating rates used in the TGA 
experiments (from 2 to 20 °C/min) and indicates that ACV form 
VI recrystallises to ACV form V, which was confirmed using 
variable temperature FTIR studies (Figure 6). 
 




ACV form Unit Dehydratation Phase transition Melting onset 
ACV I T [°C] - 171.0 (ACV form I ® IV) 255.1 (ACV form IV) 
ΔH [kJ/mol] - 2.3 33.5 
ACV II T [°C] - - 254.1-256.7 (ACV form II) 
ΔH [kJ/mol] - - 33.3-39.5   
ACV V T [°C] 58-155 168.9 (ACV form III ® IV) 254.5 (ACV form IV) 
ΔH [kJ/mol] 28.9 2.0 36.3 
ACV VI T [°C] 50-90 173.0 (ACV form V ® IV); 
200.0 (ACV form IV ® VII) 
251.3 (ACV form VII) 
ΔH [kJ/mol] 62.4 1.8 
4.8 
32.3 
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The recorded water loss in the first step agrees with the 
theoretical water loss of form VI to form V transition (i.e. 9.1 
%wt). The heating of dihydrate in a closed pan at 5 °C/min 
shows two peritectic dissociation/transformation processes, 
first at ca. 66 °C (10.2 kJ/mol) (see ESI Figure S3) followed by a 
second peritectic dissociation endothermic event at 174 °C. The 
two endothermic events displayed in the temperature range 
from 90 to 160 °C when heating in the pierced pan are followed 
by an endothermic phase transition with an onset at 173.0 °C, 
which may be related to the formation of form IV. Further 
heating of the material leads to another exothermic 
transformation at ca. 210 °C, followed by melting at 251.3 °C 
(Figure 4).  
Due to significant differences in the temperature driven 
transitions between both ACV hydrates (forms V and VI), we 
used variable temperature FTIR to further investigate the 
nature of thermal events observed in the DSC thermograms. 
The reference FTIR spectra acquired for ACV forms I, II and V 
agree with FTIR spectra published by Lutker et al. Furthermore, 
VT FTIR studies enabled us to record the previously unknown 
(to the best of our knowledge) FTIR spectra of the high 
temperature phases, i.e. forms III, IV and a new high 
temperature form VII, which was only obtained by heating ACV 
dihydrate (form VI) above 220 °C. The major spectral differences 
between the polymorphs of ACV are observed in three main 
regions: (i) 3600-3000 cm-1 where NH vibrational bands are 
observed, (ii) 1750-1650 cm-1 characteristic of carbonyl 
stretching and (iii) 1650-1250 cm-1 arising from alterations in NH 
bending, C=C and carbonyl stretching and CH bending (Figure 
5). ACV form I shows four intense vibrational bands at 3430, 
3387, 3187 and 3089 cm-1 as compared to six low intensity 
peaks of form II in the spectral range from 3500 to 3000 cm-1. 
Similarly to form II, both ACV hydrates display rather complex 
spectra with several low intensity peaks in this spectral range. 
Characteristic for both hydrates are peaks at 3530 (form V), 
3513 (form VI) and 3470 cm-1 (both V and VI), which are not 
present in anhydrous forms of ACV. Furthermore, the 
vibrational bands assigned to the carbonyl groups of hydrates 
(1750-1650 cm-1) are broader, of lower intensity and 
asymmetrically shifted towards higher wavenumbers (1702 and 
1718 cm-1) as compared to forms I and II. This may be due to 
water molecules in the structure forming stronger hydrogen 
bonds with the carbonyl group, leading to the peak shift 
towards higher frequencies.4 The FTIR spectra in the range from 
1650 to 1250 cm-1 of both hydrates and form II are significantly 
more complex as compared to ACV form I, which may be related 
to the presence of more than one molecule in the asymmetric 
unit of these forms.  
VT FTIR spectroscopy of ACV form V confirmed the formation of 
two metastable phases during dehydration of this 3:2 hydrate, 
i.e. forms III and IV, in agreement with DSC studies and previous 
research4,5. The metastable form III, first observed by Lutker et 
al.4 and Terada et al.5 upon desolvation of ACV form V, displays 
similar FTIR spectra to those of form I at temperatures above 
120 °C, indicating structural similarity of both phases. This is also 
corroborated by similarity between VT PXRD patterns of ACV 
form I and ACV form III presented by Lutker et al.4 and Terada 
et al.5 Although metastable form III display broadened FTIR 
peaks, which may be due to the loss of long range ordering upon 
desolvation, the differences in the spectral regions between 
3600 and 3000 cm-1, 1700 and 1650 cm-1 and 1150 to 800 cm-1 
enable us to exclude the possibility of formation of low 
crystallinity phase I upon desolvation of form V (see ESI Figure 
S10).  
Further heating of the material leads to the formation of the 
high temperature form IV, with an FTIR spectrum very distinct 
from form III. This transition is consistent with the phase change 
observed in the DSC thermogram at ca. 170 °C. Heating of ACV 
dihydrate (form VI) results in a behaviour very different from 
form V. The first step of dehydration is observed at ca. 60 °C, 
leading to form V, as indicated by the FTIR spectra. This 
observation is similar to the desorption studies performed by 
Terada et al., in which ACV dihydrate underwent dehydration to 
ACV 3:2 hydrate at ca. 20% RH.5
 
Figure 6. Variable temperature FTIR spectra of A. ACV form V and B. ACV form VI (see also ESI Figure S16). 
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Interestingly, as observed in the VT FTIR spectra obtained, form 
V does not undergo any further change until it reaches ca. 170 
°C. Conversely, the DSC thermograms show that when form V is 
made from form VI, it undergoes at least two transitions in the 
temperature range from 100 to 160 °C. This may be related to 
the water loss observed in the TGA, in a range of temperatures 
similar to that for form V (Figure 4B). Heating of the material 
above 210 °C results in further phase change as indicated in the 
significant changes in the FTIR spectra and corroborated by 
exothermic event in the DSC thermogram. The observed 
differences in FTIR peaks broadening between high 
temperature spectra of forms V and VI may indicate different 
ordering in both dehydration products. This may affect further 
transitions of both phases as structural disorder is one of the 
factors influencing the recrystallisation patters.  
Solution-mediated phase transformation of ACV forms V and I – 
the effect of water 
The SMPT is a three-step process – the first stage is the 
dissolution of the less stable (metastable) form, followed by 
nucleation and growth of another more stable form.14,27 Each of 
the steps may limit the rate of transformation.14 As indicated by 
Gu et al. a specific polymorphic form of a substance 
preferentially crystallizes from a specific solvent, even when no 
seeds of this form are in the crystallization medium. The reason 
of this phenomenon has been attributed to impact of solvent–
solute interactions on the solution mediated polymorphic 
transformation.10,14 
To date three studies which describe ACV polymorphism in the 
context of temperature and humidity driven phase transitions 
and polymer heteronucleation have been published.3–5 
Although, these studies provide an overview of temperature 
driven phase transitions and identify several different 
crystalline structures of this drug, no systematic study of solvent 
driven phase transitions has been carried out so far. Such study 
is valuable both in the academic and industrial contexts, as 
several liquid and semi-solid formulations of ACV are available 
on the market and significant differences in dissolution kinetics 
between polymorphs of ACV have been observed.2,3 ACV form I 
slurried in MeOH (at aw £0.14), NNDMF and DMSO results in the 
formation of form II after one to four weeks (Figure 7), while 
slurrying in other 11 organic solvents did not result in a phase 
change (see Scheme 1A, and ESI Figures S26-27). Slurrying of 
form I in DMSO resulted in the formation of an opaque gel-like 
material, containing highly crystalline form II (Figure 8 and 
Figure 9). Transition of form I to form II in MeOH was dependent 
on water activity (see ESI Section S4). The mixture of forms I, II 
and V was detected at aw ≥ 0.18 with increasing content of ACV 
3:2 hydrate at higher aw (≥0.24). The formation of ACV form II in 
NNDMF was observed at aw £ 0.38.  
Slurrying of ACV form V in dry MeOH, EtOH and NNDMF results 
in dehydration and the formation of form I, which was 
confirmed by PXRD, FTIR, DSC and TGA (Figure 8, ESI Figures 
S17-20). The phase change from form V to form I is observed 
only in dry solvents stored at RH below 40%, which corresponds 
to aw £ 0.1 in MeOH and aw < 0.22 in NNDMF (see ESI Figures S6 
and S7). The increase of water content in the solvent, which may 
occur upon sorption of water from ambient atmosphere, 
prevents the form V to form I transition. This phenomenon was 
most notable for MeOH, in which the phase transition would 
not occur when stored above 40% RH. Interestingly, once form 
I is produced in dry MeOH (or EtOH to a lesser extent), an 
increase of water content in the solvent drives the transition 
towards the dihydrate form VI (see ESI Figures S18-19), which 
also can be formed during form I slurrying in water (Figure 7). A 
mixture of forms I and VI was also obtained by Lutker et al. when 
form V was recrystallised in a mixture of MeOH and Nylon 6 as 
a source of heteronuclei.4 The complete transition of form V to 
form I in NNDMF was observed after the first week of storage, 
while in EtOH and MeOH the transformation took about four 
weeks to complete (see ESI Figures S18-19). The quick 
dehydration of form V in NNDMF may be due to its high water 
affinity, frequently utilised in dehydration processes in organic 
synthesis.28 Slurrying form V in PrOH resulted in a mixture of 
forms I and V after the first week, which did not undergo any 
phase change over the next four weeks of the experiment (see 
ESI Figure S21).  
 
Scheme 1. Solvent mediated phase transitions of ACV forms I (A.) and V (B.). 
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Figure 7. A: FTIR spectra and B. PXRD patterns of ACV form I slurried for four weeks in NNDMF, MeOH, EtOH, DMSO and water. The FTIR spectra and PXRD patterns of 
forms I and V along with the calculated PXRD pattern of ACV form II (CSD ref. MECWIC035)are given for comparison. 
Slurrying form V in DMSO resulted in the formation of an 
opaque, gel-like material composed of high crystallinity ACV 
form II suspended in the solvent, as confirmed using FTIR, PXRD 
and solid-state NMR (see Figure 3, Figures 7 and 8 and ESI Figure 
S22). Slurrying of form V in nine other organic solvents and 
water (Scheme 1B) did not produce any phase change during up 
to six weeks of experimental time (see ESI Figures S21-22). 
Based on the results of the control experiments of form V 
slurrying in MeOH/water and NNDMF/water mixtures at 
different aw, it was demonstrated that transition of form V to 
form I is only possible at aw £ 0.1 in MeOH and at aw £ 0.22 in 
NNDMF (ESI Figure S7).To verify this further, we performed 
additional slurry experiments in water, which demonstrated 
that form I suspended in water forms the dihydrate (form VI) 
rather than the 3:2 ACV:water hydrate (form V). Furthermore, 
the addition of seeds of form V to form I suspended in water 
resulted in a mixture of form V and form VI after a week of 
storage. This indicates that water drives the transition of form I 
into dihydrate, even in the presence of the 3:2 ACV:water 
hydrate, which is the commercially available stable form of ACV.
 
Figure 8. A: FTIR spectra and B. PXRD patterns of ACV form V slurried for four weeks in NNDMF, MeOH, DMSO and water. The FTIR spectra and PXRD traces of ACV 
form I and form V along with the calculated PXRD pattern of ACV form II (CSD ref. MECWIC035)are given for comparison. 
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Figure 9. ACV gels in DMSO obtained from ACV form V (A.) and form I (B.) 
Despite several attempts the transition from form V to form II 
in MeOH and NNDMF was never observed during the slurry 
experiments performed at ca. 22 °C (up to 6 weeks of storage). 
The formation of ACV form II from form V in MeOH and NNDMF 
was only observed after seeding with form II or in dry solvent 
after six days of intensive mixing at 35 °C (see ESI Figures S8 and 
S9).This may be attributed to the much longer time required for 
the system to equilibrate in the presence of water, which is 
released to the solution from ACV form V upon transition to 
form I or to a high energy barrier required to form stable nuclei 
of form II.  In a control experiment ACV form I was slurried in 
MeOH and NNDMF at aw range from 0.03 to 0.38, and after a 
week of storage traces of ACV form V were detected in 
MeOH/water mixtures at aw ≥ 0.18 and no phase change to form 
II was observed. The analysis of the results on form V to form I 
transformations, in the context of solvent properties, points 
towards the following characteristics as determining the 
outcome of the phase transitions. Complete transformations to 
form I were detected in NNDMF, EtOH and MeOH, while a 
partial transition was observed in PrOH. Among the selected 
alcohols used in the slurry experiments, MeOH and EtOH show 
the highest dielectric constants and values of δP and δH Hansen 
solubility parameters. Similarly, a high value of dielectric 
constant (37.22) and δP (13.7) in NNDMF may be correlated 
with transformation of form V to form I. Therefore, the 
combination of the high dielectric constant of the solvent (in the 
range from 20 to 37) with favourable hydrogen bonds and 
dipolar properties as described using respective Hansen 
solubility parameters (δH of 11 MPa0.5, δP ca. 9 MPa0.5) may be 
of importance in determining the outcome of the ACV form V 
transitions mediated by different solvents. The transformation 
of form I towards form II in NNDMF, MeOH and DMSO highlight 
the importance of the high dielectric constant of the solvent 
required for the phase change. Furthermore, the presence of 
water in both NNDMF and MeOH blocks this polymorphic 
transformation. The higher thermodynamic stability of the 
hydrate forms V and VI in the presence of water may explain the 
inhibition of the conversion between anhydrous forms I and II, 
as traces of form VI were observed in the PXRD patterns of ACV 
form V slurried in MeOH and EtOH after 6 weeks of storage. 
Structural view on the transformations of ACV (Figure 10). The 
dehydration of form V (3:2 ACV:water hydrate), the 
commercially available form of ACV to form I can be performed 
either via thermal treatment or using organic solvents with high 
dielectric constant, namely NNDMF (at aw £ 0.22), EtOH and 
MeOH (at aw £ 0.1). The two distinct water molecules present 
in the crystal structure of form V occupy channels along the b 
axis, partially blocked by the aliphatic chains of ACV molecules. 
One of the water molecules (Figure 10, blue water molecule) 
links the hydroxyl groups of two ACV molecules with parallel 
alignment of their purine rings (Scheme 2, purple and yellow 
molecules). A third ACV molecule, with an antiparallel 
alignment of its purine ring (Figure 10, green molecule), is 
inserted between two parallel ones, forming stacking 
interactions with both. The same water molecule donates a 
hydrogen to a carbonyl group (C2=O) of an ACV (yellow) 
molecule and accepts one from an amino group in neighbouring 
stacks. The other symmetry-independent water molecule (red) 
is involved in three hydrogen bonds with three ACV molecules 
from three different stacks. It donates to a hydroxyl group and 
a carbonyl group (C2), and accepts from an amino group. Each 
ACV molecule in the structure forms hydrogen bonded dimers 
with two neighbouring molecules. The dimers are held together 
by R22(9) rings of (amide)N-H…N(imidazole) and NH2…O=C2 
hydrogen bonds. The molecules in each resulting zig-zag chain 
have their aliphatic groups pointing in alternating directions. 
Removal of water from this structure results in form I (Z’=1), 
which presents a very similar chain of ACV dimers to those in 
form V. On the other hand, the purine rings of stacked ACV 
molecules in form I display an antiparallel (ABAB) alignment, 
while in form V two out of three ACV molecules have their 
purine rings aligned parallel and the third in an antiparallel 
alignment (AABAAB). Despite form I being formed after 
dehydration of form V, there are significant differences 
between both structures indicating the form I is not simply an 
isomorphic dehydrate of form V, but it is formed through other 
high temperature anhydrous forms or through solvent 
mediated experiments. 
Water molecules in the dihydrate are placed in wide channels 
along crystallographic a axis and form a dense network of 
hydrogen bonds with each other and with hydroxyl, carbonyl 
and amino groups of ACV molecules. Pairs of symmetry-
independent ACV molecules form hydrogen bonded dimers 
stabilized by the same hydrogen bonds as in forms V and I. The 
dimers form chains in a similar way as in forms I and V. The 
channel structure of the dihydrate explains its rapid, peritectic 
transformation to the more stable ACV form V upon heating at 
relatively low temperatures (below 80 °C) as indicated by DSC, 
TGA and FTIR.  
Anhydrous ACV form II, which is formed from form I in MeOH, 
NNDMF and DMSO and from V in DMSO, shows a different 
hydrogen bonding pattern from the other known structures of 
the drug. Each ACV molecule in the structure forms seven 
hydrogen bonds with three neighbouring molecules. 
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Figure 10. Structural differences between ACV forms. ACV forms V and I are visualised down crystallographic c axis. ACV forms VI and II are visualised down 
crystallographic a axis. See section: The summary of structural transformations of ACV for details. 
 
The R22(9) rings of (amide)N-H…N(imidazole) and NH2…O=C2 
hydrogen bonds are still present between symmetry-
independent ACV molecules, but are expanded into a complex 
network by hydroxyl to N(pyrimidine) (green molecules in 
Figure 10), hydroxyl (blue) to hydroxyl (green) and amino to 
ether oxygen bonds.  
As ACV form II shows significant structural differences from all 
other forms, it is not surprising that it is not accessible via 
thermal treatment and only solvent mediated experiments can 
produce it. The significantly different arrangement of hydrogen 
bonds requires reformation of the structure via partial 
dissolution and subsequent nucleation and crystal growth of 
ACV form II. The performed seeding experiments, in which 
addition of small amounts of form II crystals to form V or form I 
slurries, initiated and accelerated the transition towards form II 
shows that this form is most stable in MeOH and NNDMF. 
Transition from form V to form II, which was only observed after 
addition of the form II seeds, is indicative of a large energy 
barrier to form stable nuclei of form II or slow kinetics of the 
process. 
CONCLUSIONS 
The systematic investigation of solvent mediated phase 
transformations of acyclovir performed in 14 organic solvents 
indicated the dehydration of form V, which results in phase 
transformation to anhydrous form I is favoured in the highest 
polarity alcohols (MeOH and EtOH) and NNDMF while form V 
slurried in DMSO formed a gel-like material composed of 
crystalline form II. On the other hand, slurrying of form I in 
highly polar anhydrous MeOH and NNDMF resulted in transition 
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to form II along with formation of gel-like form II in DMSO. 
Increased water activity in solvents during slurrying 
experiments of ACV form I prevented the transformation to 
form II. Combining solution mediated phase transformation 
experiments with solid-state NMR analysis of obtained solid 
forms enabled us to gain a more detailed understanding of 
structural transformations of ACV. This in turn will be beneficial 
for expanding the knowledge of solid state landscape for N-
substituted purine derivatives, an important group of 
biologically and pharmaceutically active molecules.  
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